Posted by Michael Wonder on 10 Oct 2021
PHARMAC negotiates deal for molnupiravir to treat COVID-19
11 October 2021 - PHARMAC has negotiated an agreement with supplier MSD to purchase the antiviral molnupiravir.
It will be used to treat New Zealanders with mild to moderate COVID-19 symptoms, subject to the treatment gaining regulatory approval in New Zealand by Medsafe.
“Getting vaccinated is the best defence against COVID-19. But we are pleased that we have secured an additional treatment to help those who become unwell,” says PHARMAC’s Chief Executive Sarah Fitt. “The signed agreement is for an initial supply of 60,000 courses, giving Kiwis another line of defence against the virus.”
